AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28731567 — intervention group
Group type: COMPARATOR
Intervention: 8-week sham acupuncture treatment
Number of subjects: 71
Study 28731567 — intervention group
Group type: COMPARATOR
Intervention: Increased global efficiency before starting clinical treatment
Number of subjects: 71
Study 28731567 — intervention group
Group type: COMPARATOR
Intervention: Nodal efficiency in white matter network
Number of subjects: 71
Study 26648691 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole + HMG
Number of subjects: 255
Study 26648691 — intervention group
Group type: EXPERIMENTAL
Intervention: CC + HMG
Number of subjects: 255
Study 26648691 — intervention group
Group type: COMPARATOR
Intervention: HMG only
Number of subjects: 255
Study 26648691 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole + HMG and CC + HMG
Number of subjects: 255
Study 26648691 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole + HMG, CC + HMG, HMG only
Number of subjects: 255
Study 23225160 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laparoscopic set-up
Number of subjects: 36
Study 23225160 — intervention group
Group type: COMPARATOR
Intervention: SILS set-up with straight instruments
Number of subjects: 36
Study 23225160 — intervention group
Group type: COMPARATOR
Intervention: SILS set-up with articulating instruments
Number of subjects: 36
Study 23225160 — intervention group
Group type: COMPARATOR
Intervention: SILS set-up after prior training with conventional laparoscopy
Number of subjects: 36
Study 21239405 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of ECG strain
Number of subjects: 7265
Study 21239405 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of ECG strain
Number of subjects: 7265
Study 21239405 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of new ECG strain
Number of subjects: 7265
Study 21239405 — intervention group
Group type: COMPARATOR
Intervention: No ECG strain
Number of subjects: 7265
Study 19276209 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0
Study 19276209 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic tools for addressing ICD cost issues
Number of subjects: 0
Study 17164574 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 36
Study 17164574 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 36
Study 14992088 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 mg ascorbic acid intravenously before applying local anesthetics
Number of subjects: 72
Study 14992088 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine and bupivacaine for plexus anesthesia
Number of subjects: 72
Study 14992088 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/ml ascorbic acid in vitro with o-toluidine
Number of subjects: 72
Study 14992088 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/ml ascorbic acid in vitro with o-toluidine
Number of subjects: 72
Study 10898050 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 22
Study 10898050 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 22
Study 9123949 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational support program
Number of subjects: 43
Study 9123949 — intervention group
Group type: COMPARATOR
Intervention: Structured diabetes education program only
Number of subjects: 43
Study 1496538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (daily 6 g, 30% C20:5 omega‐3 and 20% C22:6 omega‐3 as their methyl esters)
Number of subjects: 88
Study 1496538 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil (daily 6g [63% C8:0 and 36% C10:0])
Number of subjects: 88
Study 1496538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (daily 6 g)
Number of subjects: 88
Study 1496538 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil (daily 6g)
Number of subjects: 88
Study 6363949 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg methylprednisolone (MP) daily for 4 days
Number of subjects: 18
Study 6363949 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg methylprednisolone (MP) daily for 4 days
Number of subjects: 18
Study 6363949 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg methylprednisolone (MP)
Number of subjects: 18
Study 6363949 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg methylprednisolone (MP)
Number of subjects: 18
Study 31607515 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFire FilmArray Respiratory Panel (FA RP)
Number of subjects: 133
Study 31607515 — intervention group
Group type: COMPARATOR
Intervention: Luminex NxTAG Respiratory Pathogen Panel (NxTAG RPP)
Number of subjects: 133
Study 26961365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored care package over 1.5 years
Number of subjects: 903
Study 26961365 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 903
Study 26545539 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake (3 mg/kg‐1)
Number of subjects: 7
Study 26545539 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucralose)
Number of subjects: 7
Study 23237135 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS guided DES implantation
Number of subjects: 284
Study 23237135 — intervention group
Group type: COMPARATOR
Intervention: Angiography guided DES implantation
Number of subjects: 284
Study 21827318 — intervention group
Group type: EXPERIMENTAL
Intervention: SAP with LGS
Number of subjects: 21
Study 21827318 — intervention group
Group type: COMPARATOR
Intervention: SAP without LGS
Number of subjects: 21
Study 19318453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training
Number of subjects: 34
Study 19318453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training
Number of subjects: 34
Study 19318453 — intervention group
Group type: COMPARATOR
Intervention: No exercise training (control)
Number of subjects: 34
Study 16750468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg BID (study 1)
Number of subjects: 36
Study 16750468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg BID (study 2)
Number of subjects: 36
Study 16750468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast (both studies)
Number of subjects: 36
Study 16750468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (study 1)
Number of subjects: 36
Study 16750468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (study 2)
Number of subjects: 36
Study 14755134 — intervention group
Group type: COMPARATOR
Intervention: Reboxetine (4 mg) alone
Number of subjects: 12
Study 14755134 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reboxetine (4 mg) and mirtazapine (15 mg)
Number of subjects: 12
Study 11030508 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injections to the elbow and wrist flexors
Number of subjects: 2
Study 9085752 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided coronary stent placement
Number of subjects: 0
Study 9085752 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided therapy
Number of subjects: 0
Study 7902645 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 262
Study 7902645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 3911699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK)
Number of subjects: 60
Study 3911699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31333252 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of drug literature abstracts
Number of subjects: 59
Study 31199792 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health volunteers (CHVs) home visits
Number of subjects: 1956
Study 31199792 — intervention group
Group type: COMPARATOR
Intervention: Control communities (no CHVs home visits)
Number of subjects: 1956
Study 31199792 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health volunteers (CHVs) home visits with ≥70% coverage and ≥30-minute visit duration
Number of subjects: 1956
Study 27572887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) - Tinzaparin sodium 4500 IU subcutaneous daily injection with 500 µg folic acid once daily orally, started once positive pregnancy test till the 20th week of gestation.
Number of subjects: 300
Study 27572887 — intervention group
Group type: COMPARATOR
Intervention: Folic acid alone (same dosage as in intervention group).
Number of subjects: 300
Study 26321751 — intervention group
Group type: EXPERIMENTAL
Intervention: Flare present
Number of subjects: 508
Study 22813429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (specific dosage and duration not mentioned)
Number of subjects: 0
Study 21166928 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose atorvastatin (40 mg daily)
Number of subjects: 40
Study 21166928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18359417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas species
Number of subjects: 739
Study 18359417 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug-resistant (MDR) organisms
Number of subjects: 739
Study 18359417 — intervention group
Group type: COMPARATOR
Intervention: Pseudomonas
Number of subjects: 739
Study 18359417 — intervention group
Group type: COMPARATOR
Intervention: MDR organisms
Number of subjects: 739
Study 18359417 — intervention group
Group type: COMPARATOR
Intervention: Appropriate empirical antibiotic therapy
Number of subjects: 739
Study 18359417 — intervention group
Group type: COMPARATOR
Intervention: 28-day mortality
Number of subjects: 739
Study 18359417 — intervention group
Group type: COMPARATOR
Intervention: Hospital mortality
Number of subjects: 739
Study 18359417 — intervention group
Group type: COMPARATOR
Intervention: Duration of mechanical ventilation
Number of subjects: 739
Study 18359417 — intervention group
Group type: COMPARATOR
Intervention: ICU length of stay
Number of subjects: 739
Study 18359417 — intervention group
Group type: COMPARATOR
Intervention: Hospital length of stay
Number of subjects: 739
Study 16431933 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise assessment after marathon completion
Number of subjects: 14
Study 14499416 — intervention group
Group type: EXPERIMENTAL
Intervention: rectal placebo (RP)
Number of subjects: 13
Study 14499416 — intervention group
Group type: EXPERIMENTAL
Intervention: rectal lidocaine (RL)
Number of subjects: 13
Study 14499416 — intervention group
Group type: EXPERIMENTAL
Intervention: oral lidocaine (OL)
Number of subjects: 13
Study 14499416 — intervention group
Group type: COMPARATOR
Intervention: natural history (NH)
Number of subjects: 13
Study 14499416 — intervention group
Group type: COMPARATOR
Intervention: rectal nocebo (RN)
Number of subjects: 13
Study 10853679 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised walking exercise (4-week program)
Number of subjects: 40
Study 10853679 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 40
Study 9239162 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (KYT) administered for 5 consecutive days (Group B)
Number of subjects: 40
Study 9239162 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (KYT) administered on day 1 (Group A)
Number of subjects: 40
Study 12959314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular picenadol 50 mg
Number of subjects: 60
Study 12959314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 100 mg
Number of subjects: 60
Study 12959314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3546747 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue drug therapy and reduce overweight, excess salt, and alcohol (Group 1)
Number of subjects: 0
Study 3546747 — intervention group
Group type: COMPARATOR
Intervention: Discontinue drug therapy with no nutritional program (Group 2)
Number of subjects: 0
Study 3546747 — intervention group
Group type: COMPARATOR
Intervention: Continue drug therapy with no nutritional program (Group 3)
Number of subjects: 0
Study 28988424 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella 2.5 axial flow pump
Number of subjects: 445
Study 28988424 — intervention group
Group type: COMPARATOR
Intervention: Intra-aortic balloon pump
Number of subjects: 445
Study 28934945 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua walking (AW)
Number of subjects: 60
Study 28934945 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill/track walking (TW)
Number of subjects: 60
Study 28934945 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 60
Study 26241693 — intervention group
Group type: EXPERIMENTAL
Intervention: Freestyle Navigator II CGM
Number of subjects: 57
Study 23164722 — intervention group
Group type: EXPERIMENTAL
Intervention: Single suture anchors
Number of subjects: 50
Study 23164722 — intervention group
Group type: EXPERIMENTAL
Intervention: Double suture anchors
Number of subjects: 50
Study 21044929 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy (MC)
Number of subjects: 60
Study 21044929 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 60
Study 18474682 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Tanshinol (TSL) from cardiotonic pills
Number of subjects: 0
Study 18474682 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Tanshinol (TSL) from cardiotonic pills
Number of subjects: 0
Study 18474682 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary recovery of Tanshinol (TSL) in humans
Number of subjects: 0
Study 18474682 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorption rate and bioavailability of Tanshinol (TSL)
Number of subjects: 0
Study 18474682 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal excretion of Tanshinol (TSL)
Number of subjects: 0
Study 18474682 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA (Protocatechuic aldehyde)
Number of subjects: 0
Study 18474682 — intervention group
Group type: EXPERIMENTAL
Intervention: Other phenolic acids from Danshen
Number of subjects: 0
Study 17052637 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg (1 mL) added to articaine 4%, 1:100:000 epinephrine, 1.5 cartridges (2.7 mL)
Number of subjects: 48
Study 17052637 — intervention group
Group type: COMPARATOR
Intervention: Articaine 4%, 1:100:000 epinephrine, 1.5 cartridges (2.7 mL) and saline (1 mL)
Number of subjects: 48
Study 14603582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of omeprazole plus diclofenac
Number of subjects: 0
Study 14603582 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 0
Study 14603582 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI with other nonselective NSAIDs
Number of subjects: 0
Study 14603582 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX‐2 inhibitor with a PPI or misoprostol
Number of subjects: 0
Study 14635273 — intervention group
Group type: EXPERIMENTAL
Intervention: Monarch valgus loading knee brace
Number of subjects: 5
Study 14635273 — intervention group
Group type: COMPARATOR
Intervention: Unbraced condition
Number of subjects: 5
Study 7710561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (14 mmol/l)
Number of subjects: 10
Study 7710561 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycaemia (5 mmol/l)
Number of subjects: 10
Study 7710561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (2.5 mmol/l)
Number of subjects: 10
Study 1709903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized heparin (800 IU per kg b.w.) administered by inhalation one day prior to surgery
Number of subjects: 183
Study 1709903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized heparin (800 IU per kg b.w.) + long acting anabolic steroid (50 mg nandrolone phenylpropionate) intramuscularly
Number of subjects: 183
Study 1709903 — intervention group
Group type: COMPARATOR
Intervention: 5000 IU heparin subcutaneously on hr prior to surgery and every 12 h for the next 5 postoperative days
Number of subjects: 183
Study 1709903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized heparin (800 IU per kg b.w.)
Number of subjects: 183
Study 1709903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized heparin (800 IU per kg b.w.) + long acting anabolic steroid (50 mg nandrolone phenylpropionate)
Number of subjects: 183
Study 345412 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 143
Study 345412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 143
Study 345412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 143
Study 345412 — intervention group
Group type: COMPARATOR
Intervention: Diazepam alone
Number of subjects: 143
Study 31621973 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-less approach
Number of subjects: 40
Study 31621973 — intervention group
Group type: COMPARATOR
Intervention: Printed model digital approach
Number of subjects: 40
Study 31621973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both workflows
Number of subjects: 40
Study 31621973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 40
Study 28731561 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index (GI)
Number of subjects: 1618
Study 28731561 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-adjusted glycaemic load (GL)
Number of subjects: 1618
Study 26695922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (30 mg three times per day) and Essenciale (600 mg twice daily) for 6 months
Number of subjects: 60
Study 26695922 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 60
Study 23756392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine 12.5 mg three times daily for 8 weeks
Number of subjects: 100
Study 23756392 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 100
Study 21252141 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-based ART (600 mg)
Number of subjects: 168
Study 21252141 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine-based ART (400 mg)
Number of subjects: 168
Study 21252141 — intervention group
Group type: EXPERIMENTAL
Intervention: Both efavirenz and nevirapine-based ART
Number of subjects: 168
Study 18278626 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school physical activity intervention including 40 min of academic enrichment and 80 min of moderate-to-vigorous physical activity (MVPA)
Number of subjects: 206
Study 18278626 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school physical activity intervention
Number of subjects: 206
Study 18278626 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study 16920865 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron+folic acid (FeFA) (12.5 mg Fe + 50 mug folic acid)
Number of subjects: 354
Study 16920865 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron+folic acid (FeFA) with or without Zinc (Zn) (10 mg)
Number of subjects: 354
Study 16920865 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron+folic acid (FeFA) alone
Number of subjects: 354
Study 16920865 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (Zn) alone
Number of subjects: 354
Study 16920865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 12712025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg, maximum dose 10 mg)
Number of subjects: 184
Study 12712025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 11061879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide
Number of subjects: 21
Study 11061879 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 21
Study 9255435 — intervention group
Group type: EXPERIMENTAL
Intervention: RheothRx Injection (0.5 mg/ml)
Number of subjects: 46
Study 9255435 — intervention group
Group type: EXPERIMENTAL
Intervention: RheothRx Injection (1 mg/ml)
Number of subjects: 46
Study 9255435 — intervention group
Group type: EXPERIMENTAL
Intervention: RheothRx Injection (2 mg/ml)
Number of subjects: 46
Study 9255435 — intervention group
Group type: EXPERIMENTAL
Intervention: RheothRx Injection (5 mg/ml)
Number of subjects: 46
Study 9255435 — intervention group
Group type: EXPERIMENTAL
Intervention: RheothRx Injection (during CORE Trial)
Number of subjects: 46
Study 8345429 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus platelet concentrates (10 ml/kg)
Number of subjects: 152
Study 8345429 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 152
Study 2942168 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally-administered nickel (5.6 mg)
Number of subjects: 8
Study 2942168 — intervention group
Group type: COMPARATOR
Intervention: Lower doses of nickel
Number of subjects: 8
Study 2942168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30580652 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (CUR)
Number of subjects: 14
Study 30580652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30580652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual Stress Challenge (DSC)
Number of subjects: 14
Study 30052598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed session periodization (MSP)
Number of subjects: 45
Study 30052598 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional periodization (TP)
Number of subjects: 45
Study 30052598 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 26835724 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket-sized ultrasound system
Number of subjects: 40
Study 26835724 — intervention group
Group type: COMPARATOR
Intervention: High-end ultrasound system
Number of subjects: 40
Study 25052387 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth group (TG)
Number of subjects: 45
Study 25052387 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45
Study 25052387 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth group (TG) for patients without comorbidity
Number of subjects: 45
Study 25052387 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) for patients without comorbidity
Number of subjects: 45